Eviive

EVIIVE, established in 2022, is a pioneering company in the BioMed Tech sector, specializing in liquid biopsy biomarker discovery. The company focuses on developing assay kits tailored for individualized treatment recommendations and disease tracking. EVIIVE's groundbreaking technology aims to elevate personalized diagnostic solutions, providing comprehensive insights that gain industry leader endorsement and reliance. The company serves clients in the healthcare and biomedical research sectors, targeting markets that require advanced diagnostic tools for immune system defects and disease detection. EVIIVE operates on a B2B business model, generating revenue through the sale of its diagnostic assay kits and platform services. The company has received significant funding and support from prestigious institutions such as the UZH BIOMEDTECH fellowship and the WYSS foundation, which has enabled it to further develop its technology and accelerate market entry.

Keywords: liquid biopsy, biomarker discovery, personalized diagnostics, disease tracking, assay kits, BioMed Tech, immune system defects, healthcare, biomedical research, B2B.